Who is sponsoring NCT07351786?

NCT07351786 is sponsored by Sara A Belal.

What condition does NCT07351786 study?

NCT07351786 studies Diabetes (DM), Retinopathy, Diabetic, Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus.

What is the status of NCT07351786?

NCT07351786 is currently RECRUITING.

Last reviewed 2026-01-12 · How we verify

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

NCT07351786 RECRUITING

This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.

Details

Lead sponsor	Sara A Belal
Status	RECRUITING
Enrolment	70
Start date	2025-08-01
Completion	2026-09

Conditions

Diabetes (DM)
Retinopathy, Diabetic
Diabetic Retinopathy (DR)
Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus

Primary outcomes

The level of diabetic retinopathy, measured using Optos Ultra-widefield (UWF) Retinal Imaging, reported as ICDR (International Clinical Diabetic Retinopathy) score (0-4 scale). — Assessed once per participant at baseline.
Where 0 indicates no apparent diabetic retinopathy and 4 indicates proliferative diabetic retinopathy; higher scores indicate more severe (worse) diabetic retinopathy.

Countries

Egypt